NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis $1.85 +0.11 (+6.32%) Closing price 04:00 PM EasternExtended Trading$1.86 +0.01 (+0.54%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Curis Stock (NASDAQ:CRIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Curis alerts:Sign Up Key Stats Today's Range$1.69▼$1.9050-Day Range$1.74▼$2.8052-Week Range$1.02▼$8.29Volume168,278 shsAverage Volume81,285 shsMarket Capitalization$19.35 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingBuy Company Overview Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Read More Curis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreCRIS MarketRank™: Curis scored higher than 58% of companies evaluated by MarketBeat, and ranked 430th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCuris has only been the subject of 1 research reports in the past 90 days.Read more about Curis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($7.12) to ($3.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Curis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently decreased by 10.57%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.24% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently decreased by 10.57%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.20 News SentimentCuris has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Curis this week, compared to 1 article on an average week.Search Interest3 people have searched for CRIS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 29.97% of the stock of Curis is held by institutions.Read more about Curis' insider trading history. Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Stock News HeadlinesCuris Announces $7.0 Million Registered Direct and Concurrent Private Placement - Seeking AlphaJuly 4, 2025 | seekingalpha.comCuris Announces $7M Securities Purchase AgreementJuly 4, 2025 | theglobeandmail.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 8 at 2:00 AM | Porter & Company (Ad)Curis Announces $7.0 Million Registered Direct and Concurrent Private PlacementJuly 2, 2025 | prnewswire.comCURIS Earnings Preview: Recent $CRIS Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comCuris’s Strategic Clinical Advancements and Positive Regulatory Feedback Underpin Buy RatingMay 8, 2025 | tipranks.comEarnings call transcript: Curis Inc. Q1 2025 sees stock surge despite lossesMay 7, 2025 | uk.investing.comCuris highlights progress in lymphoma and AML trials with expanded patient enrollmentMay 7, 2025 | msn.comSee More Headlines CRIS Stock Analysis - Frequently Asked Questions How have CRIS shares performed this year? Curis' stock was trading at $3.06 at the start of the year. Since then, CRIS stock has decreased by 39.5% and is now trading at $1.85. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Tuesday, May, 6th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.14) by $0.11. The biotechnology company earned $2.38 million during the quarter, compared to analyst estimates of $2.37 million. Read the conference call transcript. When did Curis' stock split? Curis shares reverse split on the morning of Friday, September 29th 2023.The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Micron Technology (MU), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/06/2025Today7/08/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees60Year Founded2000Price Target and Rating Average Price Target for Curis$17.00 High Price Target$17.00 Low Price Target$17.00 Potential Upside/Downside+818.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($6.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.39 million Net Margins-376.08% Pretax Margin-376.08% Return on EquityN/A Return on Assets-97.14% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual Sales$10.91 million Price / Sales1.77 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-2.61Miscellaneous Outstanding Shares10,460,000Free Float9,866,000Market Cap$19.35 million OptionableNo Data Beta3.60 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:CRIS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.